SAREPTA THERAPEUTICS INC (SRPT)

US8036071004 - Common Stock

127.86  -2.37 (-1.82%)

Fundamental Rating

3

SRPT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 592 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. SRPT is valued quite expensively, but it does show have an excellent growth rating.



2

1. Profitability

1.1 Basic Checks

In the past year SRPT has reported negative net income.
In the past year SRPT has reported a negative cash flow from operations.
In the past 5 years SRPT always reported negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -16.42%, SRPT belongs to the top of the industry, outperforming 85.20% of the companies in the same industry.
SRPT's Return On Equity of -62.37% is in line compared to the rest of the industry. SRPT outperforms 58.84% of its industry peers.
Industry RankSector Rank
ROA -16.42%
ROE -62.37%
ROIC N/A
ROA(3y)-17.4%
ROA(5y)-22%
ROE(3y)-96.74%
ROE(5y)-90.07%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of SRPT (87.91%) is better than 91.50% of its industry peers.
In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.13%
GM growth 5Y-0.17%

3

2. Health

2.1 Basic Checks

SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRPT has been increased compared to 1 year ago.
SRPT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SRPT has been reduced compared to a year ago.

2.2 Solvency

SRPT has an Altman-Z score of 1.96. This is not the best score and indicates that SRPT is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 1.96, SRPT is doing good in the industry, outperforming 67.86% of the companies in the same industry.
A Debt/Equity ratio of 1.32 is on the high side and indicates that SRPT has dependencies on debt financing.
SRPT has a worse Debt to Equity ratio (1.32) than 81.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF N/A
Altman-Z 1.96
ROIC/WACCN/A
WACC8.57%

2.3 Liquidity

A Current Ratio of 3.95 indicates that SRPT has no problem at all paying its short term obligations.
With a Current ratio value of 3.95, SRPT perfoms like the industry average, outperforming 43.03% of the companies in the same industry.
A Quick Ratio of 3.45 indicates that SRPT has no problem at all paying its short term obligations.
SRPT's Quick ratio of 3.45 is on the low side compared to the rest of the industry. SRPT is outperformed by 60.20% of its industry peers.
Industry RankSector Rank
Current Ratio 3.95
Quick Ratio 3.45

7

3. Growth

3.1 Past

SRPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.79%, which is quite impressive.
SRPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 33.26%.
Measured over the past years, SRPT shows a very strong growth in Revenue. The Revenue has been growing by 32.80% on average per year.
EPS 1Y (TTM)23.79%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q137.9%
Revenue 1Y (TTM)33.26%
Revenue growth 3Y32.04%
Revenue growth 5Y32.8%
Revenue growth Q2Q53.55%

3.2 Future

Based on estimates for the next years, SRPT will show a very strong growth in Earnings Per Share. The EPS will grow by 27.33% on average per year.
SRPT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.22% yearly.
EPS Next Y141.21%
EPS Next 2Y93.66%
EPS Next 3Y61.17%
EPS Next 5Y27.33%
Revenue Next Year51.52%
Revenue Next 2Y55.82%
Revenue Next 3Y42.22%
Revenue Next 5Y24.22%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 50.70, which means the current valuation is very expensive for SRPT.
Based on the Price/Forward Earnings ratio, SRPT is valued cheaply inside the industry as 94.22% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.74. SRPT is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 50.7

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SRPT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SRPT's earnings are expected to grow with 61.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y93.66%
EPS Next 3Y61.17%

0

5. Dividend

5.1 Amount

SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (3/28/2024, 1:18:28 PM)

127.86

-2.37 (-1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.00B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 50.7
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.42%
ROE -62.37%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 87.91%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.95
Quick Ratio 3.45
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)23.79%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y141.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)33.26%
Revenue growth 3Y32.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y